HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS British Journal of Psychiatry Psychiatric Bulletin All RCPsych Journals		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Related articles in APT Similar articles in this journal Alert me to new issues of the journal Download to citation manager Google Scholar Articles by James, A. PubMed Articles by James, A.

Pharmacotherapy and child psychiatry: is there a way forward?

INVITED COMMENTARY ON... CHILD PSYCHIATRY AND ITS RELATIONSHIP WITH THE PHARMACEUTICAL INDUSTRY

Anthony James is a consultant child and adolescent psychiatrist at Highfield Adolescent Unit (Warneford Hospital, Oxford OX3 7JX, UK. Email: tony.james{at}obmh.nhs.uk) and Honorary Senior Lecturer at the University of Oxford. His research interests include neuroimaging of early-onset psychosis, obsessive–compulsive disorder and eating disorders.

Recent controversy over the use of serotonin reuptake inhibitors in children and adolescents has focused attention on the role of the pharmaceutical industry in the treatment of young people. Failure of pharmaceutical companies to fully disclose negative outcome trials has led to new guidelines for publication of all trial results. Scrutiny is on the conduct of trials and the relationship of the pharmaceutical industry with prescribing doctors and post-trial surveillance of new drugs. It is argued that drug treatments in child psychiatry are a powerful therapeutic tool but vigilance is needed to ensure that data on the efficacy and safety of drugs are freely available.

Related articles in APT:

Child psychiatry and its relationship with the pharmaceutical industry: theoretical and practical issues

Sami Timimi
APT 2008 14: 3-9. [Abstract] [Full Text]